Depression Clinical Trial
— IMPRESSOfficial title:
IMPlementation of Evidence Based Facility and Community Interventions to Reduce the Treatment Gap for depRESSion
Verified date | May 2024 |
Source | Sangath |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this Hybrid Type 2 Implementation-Effectiveness Cluster Randomised Controlled Trial is to reduce the treatment gap for depression through the integrated implementation of interventions in facility and community platforms, in Goa, India. The primary question is to examine whether a community intervention ("Community Model") enhances the demand for, and improves the outcomes of, an evidence-based, brief psychological treatment for depression delivered by non-specialist health workers in primary health care facilities ("Facility Model"). Participants in the Facility Model arm will receive only a psychosocial intervention for depression (the Healthy Activity Program - HAP) while participants in the Community Model will receive both the HAP and the community intervention. We will compare the Facility Model and the Community Model to assess if the latter is superior in increasing the demand for depression treatment in primary care, increasing uptake of treatment by people with depression, increasing treatment completion rates, and reducing the severity of depression.
Status | Recruiting |
Enrollment | 588 |
Est. completion date | April 30, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | (A) Contact Coverage Outcome Inclusion Criteria - Adults (>18 years) - Residing in the clusters included in the trial - Speak English or one of the local languages (Konkani, Marathi, Hindi) Exclusion Criteria - Patients with significant speech, hearing, or language impairment that interferes with completion of the screening and/or receipt of psychosocial intervention - Patients who present to the health centre for emergency medical attention - Patients with active psychotic symptoms (B) Effectiveness Coverage Outcome Inclusion Criteria - Adults (>18 years); - Residing in the clusters included in the trial - Speak English or one of the local languages (Konkani, Marathi, Hindi). - Screen positive for moderately severe or severe depression (total score >14) on the Patient Health Questionnaire-9 items (PHQ-9) Exclusion Criteria - Patients with significant speech, hearing, or language impairment that interferes with completion of the screening and/or receipt of psychosocial intervention - Patients who present to the health centre for emergency medical attention - Patients with active psychotic symptoms |
Country | Name | City | State |
---|---|---|---|
India | Sangath | Goa |
Lead Sponsor | Collaborator |
---|---|
Sangath | Centre for Addiction and Mental Health, Harvard Medical School (HMS and HSDM), London School of Hygiene and Tropical Medicine |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Contact coverage | Patient Health Questionnaire 9 items (PHQ-9) score >4. The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | During recruitment | |
Primary | Effectiveness coverage | Mean Patient Health Questionnaire 9 items (PHQ-9 score). The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | Three months post recruitment | |
Secondary | Sustained effectiveness | Mean Patient Health Questionnaire 9 items (PHQ-9 score). The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | Six months post recruitment | |
Secondary | Remission | Patient Health Questionnaire 9 items (PHQ-9 score) score <10. . The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | Three months post recruitment | |
Secondary | Remission | Patient Health Questionnaire 9 items (PHQ-9 score) score <10. . The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | Six months post recruitment | |
Secondary | Response to treatment | >50% reduction in Patient Health Questionnaire 9 items (PHQ-9 score) score. The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | Three months post recruitment | |
Secondary | Response to treatment | >50% reduction in Patient Health Questionnaire 9 items (PHQ-9 score) score. The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression. | Six months post recruitment | |
Secondary | Client Service Receipt Inventory | Out-of-pocket costs for receiving care and the related non-medical costs | 3- and 6- months post recruitment | |
Secondary | WHO Disability Assessment Schedule (WHODAS 2.0) | Standardized disability scores used to estimate Quality Adjusted Life Years (QALYs). The 12-item WHODAS 2.0 score ranges from 12 to 60, where higher scores indicate higher disability or loss of function. | Baseline, 3- and 6- months post recruitment | |
Secondary | Survey form for collecting costs of receiving HAP intervention to patients | Out-of-pocket costs for receiving HAP intervention (e.g. time loss, travel) | 3 months post recruitment | |
Secondary | Inventory form for collecting system-level economic costs of delivering interventions | System-level costs: Economic costs in WHO six building blocks for delivering the interventions | Monthly, through study completion up to approximately 12 months | |
Secondary | Depression awareness | Awareness about depression. This will be a bespoke tool developed for our trial and will have questions to assess awareness related to depression based on the information disseminated in our community intervention and higher scores will indicate greater awareness. | Baseline, 6 and 12 months of implementation | |
Secondary | Perceived social support | Perception of social support received. This will be a bespoke tool developed for our trial and will have questions to assess perceived support related to support provided by community volunteers in our community intervention and higher scores will indicate greater support. | 3- and 6- months post recruitment | |
Secondary | Multidimensional Scale of Perceived Social Support (MSPSS) | 12 item short instrument designed to measure an individual's perception of support from 3 sources: family, friends and a significant other. Minimum score 12 and maximum 84 | Baseline, 3- and 6-months post-recruitment | |
Secondary | Treatment completion | Met treatment goals or completed the maximum number of sessions or were referred to mental health specialists | Across 12 months of implementation | |
Secondary | Behavioral activation | Level of behavioral activation measured using PREMIUM Abbreviated Activation Scale. This is a five-item scale, originally developed based on the Behavioural Activation for Depression Scale. It includes five self-reported indicators and the total score can range from 0 to 20. Higher scores indicate greater level of behavioural activation such as engagement with a variety of activities, and associated pleasure and mastery. | Baseline, 3- and 6- months post recruitment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |